• is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.


  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.


I have read and understood the above

Drug & research development » Clinical trials » NCT01339897

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of N6022 in Healthy Subjects

Clinical Trials gov number: NCT01339897

Click on the tabs to move through the sequence.

Purpose: To evaluate multiple doses across a range that has been found to be effective in mouse models of asthma, and safe in one Phase 1 clinical trial. It is intended to provide evidence of the tolerability of multiple doses as well as provide information on the pharmacokinetic (PK) and metabolism of N6022 in humans.

Phase: 1

Type: Interventional, randomized, double-blind, parallel assignment

Study sponsor: Nivalis Therapeutics, Inc.

  • Subject is healthy, determined by pre-study medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations)
  • Non-smoker (or other nicotine user) as determined by history (no nicotine use over the past year) and a negative urine cotinine test at screening and Day 1
  • Body weight >50 kg and BMI between 19.5 and 29.5 kg/m2, inclusive, at screening
  • Subject has systolic BP >90 mmHg and diastolic BP >50 mmHg at screening or Day-1


Geographical Location
United States

Number of Participants
≤50 (18-45 years)

Primary Endpoint

Safety of escalating multiple doses of N6022 in healthy subjects (7 days)

Secondary Endpoint

Pharmacokinetics of N602 (Day 1 and Day 7 – 24 hours)

Click on the tabs to move through the sequence.

  • Active Comparator: 5 mg/N6022 injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days
  • Placebo Comparator: Placebo injectable formulation normal saline
  • Active Comparator: 10mg/N6022 injectable formulation, given at doses of 10 mg given QD each day over 7 days
  • Active Comparator: 20mg/N6022 injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days
View Trial Results